請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51282
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉興華 | |
dc.contributor.author | Siao-Syun Guan | en |
dc.contributor.author | 官孝勳 | zh_TW |
dc.date.accessioned | 2021-06-15T13:29:22Z | - |
dc.date.available | 2021-02-26 | |
dc.date.copyright | 2016-02-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-02-04 | |
dc.identifier.citation | 1. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care 2005; 28: 164-176.
2. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. Journal of the American Society of Nephrology : JASN 2010; 21: 556-563. 3. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. The New England journal of medicine 2002; 346: 1145-1151. 4. Taft JL, Nolan CJ, Yeung SP, et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-1051. 5. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney international 1991; 39: 464-475. 6. Mauer SM, Lane P, Zhu D, et al. Renal structure and function in insulin-dependent diabetes mellitus in man. Journal of hypertension Supplement : official journal of the International Society of Hypertension 1992; 10: S17-20. 7. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clinical Diabetes 2003; 21: 186-187. 8. Ahmed MU, Brinkmann Frye E, Degenhardt TP, et al. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. The Biochemical journal 1997; 324 ( Pt 2): 565-570. 9. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146. 10. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. The New England journal of medicine 1988; 318: 1315-1321. 11. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996; 45 Suppl 3: S65-66. 12. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. The Journal of clinical endocrinology and metabolism 2008; 93: 1143-1152. 13. Busch M, Franke S, Ruster C, et al. Advanced glycation end-products and the kidney. European journal of clinical investigation 2010; 40: 742-755. 14. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. The American journal of pathology 2003; 162: 1123-1137. 15. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. The Journal of clinical investigation 2001; 108: 261-268. 16. Chung AC, Zhang H, Kong YZ, et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. Journal of the American Society of Nephrology : JASN 2010; 21: 249-260. 17. Brewis IA, Brennan P. Proteomics technologies for the global identification and quantification of proteins. Advances in protein chemistry and structural biology 2010; 80: 1-44. 18. May C, Brosseron F, Chartowski P, et al. Instruments and methods in proteomics. Methods Mol Biol 2011; 696: 3-26. 19. Nordhoff E, Egelhofer V, Giavalisco P, et al. Large-gel two-dimensional electrophoresis-matrix assisted laser desorption/ionization-time of flight-mass spectrometry: an analytical challenge for studying complex protein mixtures. Electrophoresis 2001; 22: 2844-2855. 20. Viswanathan S, Unlu M, Minden JS. Two-dimensional difference gel electrophoresis. Nature protocols 2006; 1: 1351-1358. 21. Timms JF, Cramer R. Difference gel electrophoresis. Proteomics 2008; 8: 4886-4897. 22. Coughlan MT, Yap FY, Tong DC, et al. Advanced glycation end products are direct modulators of beta-cell function. Diabetes 2011; 60: 2523-2532. 23. Han D, Moon S, Kim H, et al. Detection of differential proteomes associated with the development of type 2 diabetes in the Zucker rat model using the iTRAQ technique. Journal of proteome research 2011; 10: 564-577. 24. Covington MD, Schnellmann RG. Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury. Kidney international 2012; 81: 391-400. 25. Hojlund K, Yi Z, Lefort N, et al. Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin-resistant muscle. Diabetologia 2010; 53: 541-551. 26. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature methods 2012; 9: 671-675. 27. Chabardes-Garonne D, Mejean A, Aude JC, et al. A panoramic view of gene expression in the human kidney. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 13710-13715. 28. Chen YJ, Sheu ML, Tsai KS, et al. Advanced glycation end products induce peroxisome proliferator-activated receptor gamma down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PloS one 2013; 8: e66611. 29. Wu CT, Sheu ML, Tsai KS, et al. Salubrinal, an eIF2alpha dephosphorylation inhibitor, enhances cisplatin-induced oxidative stress and nephrotoxicity in a mouse model. Free radical biology & medicine 2011; 51: 671-680. 30. Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. Journal of the American Society of Nephrology : JASN 2000; 11: 1656-1666. 31. Sakaguchi M, Sonegawa H, Murata H, et al. S100A11, an dual mediator for growth regulation of human keratinocytes. Molecular biology of the cell 2008; 19: 78-85. 32. Coughlan MT, Thorburn DR, Penfold SA, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. Journal of the American Society of Nephrology : JASN 2009; 20: 742-752. 33. Executive summary: Standards of medical care in diabetes--2012. Diabetes care 2012; 35 Suppl 1: S4-S10. 34. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes care 2004; 27 Suppl 1: S79-83. 35. Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nature reviews Nephrology 2011; 7: 36-44. 36. Magri CJ, Fava S. The role of tubular injury in diabetic nephropathy. European journal of internal medicine 2009; 20: 551-555. 37. Cohen MP, Clements RS, Cohen JA, et al. Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia 1996; 39: 270-274. 38. Lim AK, Ma FY, Nikolic-Paterson DJ, et al. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009; 52: 1669-1679. 39. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England journal of medicine 1993; 329: 977-986. 40. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. The Journal of clinical investigation 1994; 94: 110-117. 41. Bierhaus A, Hofmann MA, Ziegler R, et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular research 1998; 37: 586-600. 42. Perez Gutierrez RM, Flores Cotera LB, Gonzalez AM. Evaluation of the antioxidant and anti-glication effects of the hexane extract from Piper auritum leaves in vitro and beneficial activity on oxidative stress and advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats. Molecules 2012; 17: 11897-11919. 43. Tesch GH, Lim AK. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. American journal of physiology Renal physiology 2011; 300: F301-310. 44. Saleh MC, Fatehi-Hassanabad Z, Wang R, et al. Mutated ATP synthase induces oxidative stress and impaired insulin secretion in beta-cells of female BHE/cdb rats. Diabetes/metabolism research and reviews 2008; 24: 392-403. 45. Funk JA, Schnellmann RG. Persistent disruption of mitochondrial homeostasis after acute kidney injury. American journal of physiology Renal physiology 2012; 302: F853-864. 46. Cruz-Topete D, List EO, Okada S, et al. Proteomic changes in the heart of diet-induced pre-diabetic mice. Journal of proteomics 2011; 74: 716-727. 47. Ohsakaya S, Fujikawa M, Hisabori T, et al. Knockdown of DAPIT (diabetes-associated protein in insulin-sensitive tissue) results in loss of ATP synthase in mitochondria. The Journal of biological chemistry 2011; 286: 20292-20296. 48. Li M, Xiao ZQ, Chen ZC, et al. Proteomic analysis of the aging-related proteins in human normal colon epithelial tissue. Journal of biochemistry and molecular biology 2007; 40: 72-81. 49. Xu C, Zhang X, Yu C, et al. Proteomic analysis of hepatic ischemia/reperfusion injury and ischemic preconditioning in mice revealed the protective role of ATP5beta. Proteomics 2009; 9: 409-419. 50. Wu HZ, Guo L, Mak YF, et al. Proteomics investigation on aristolochic acid nephropathy: a case study on rat kidney tissues. Analytical and bioanalytical chemistry 2011; 399: 3431-3439. 51. Funk JA, Odejinmi S, Schnellmann RG. SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. The Journal of pharmacology and experimental therapeutics 2010; 333: 593-601. 52. Porsolt RD, Moser PC, Castagne V. Behavioral indices in antipsychotic drug discovery. The Journal of pharmacology and experimental therapeutics 2010; 333: 632-638. 53. Rasbach KA, Schnellmann RG. Isoflavones promote mitochondrial biogenesis. The Journal of pharmacology and experimental therapeutics 2008; 325: 536-543. 54. Perrimon N, Ni JQ, Perkins L. In vivo RNAi: today and tomorrow. Cold Spring Harbor perspectives in biology 2010; 2: a003640. 55. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney international 2003; 63: 464-473. 56. Lee EK, Jeong JU, Chang JW, et al. Activation of AMP-activated protein kinase inhibits albumin-induced endoplasmic reticulum stress and apoptosis through inhibition of reactive oxygen species. Nephron Experimental nephrology 2012; 121: e38-48. 57. Lee YJ, Suh HN, Han HJ. Effect of BSA-induced ER stress on SGLT protein expression levels and alpha-MG uptake in renal proximal tubule cells. American journal of physiology Renal physiology 2009; 296: F1405-1416. 58. Lelli JL, Jr., Becks LL, Dabrowska MI, et al. ATP converts necrosis to apoptosis in oxidant-injured endothelial cells. Free radical biology & medicine 1998; 25: 694-702. 59. Preuss HG. Basics of renal anatomy and physiology. Clinics in laboratory medicine 1993; 13: 1-11. 60. Boron WF. Acid-base transport by the renal proximal tubule. Journal of the American Society of Nephrology : JASN 2006; 17: 2368-2382. 61. Dantzler WH. Regulation of renal proximal and distal tubule transport: sodium, chloride and organic anions. Comparative biochemistry and physiology Part A, Molecular & integrative physiology 2003; 136: 453-478. 62. Zhang F, Lau SS, Monks TJ. The cytoprotective effect of N-acetyl-L-cysteine against ROS-induced cytotoxicity is independent of its ability to enhance glutathione synthesis. Toxicological sciences : an official journal of the Society of Toxicology 2011; 120: 87-97. 63. Johnson-Lyles DN, Peifley K, Lockett S, et al. Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicology and applied pharmacology 2010; 248: 249-258. 64. Linardi A, Rocha e Silva TA, Miyabara EH, et al. Histological and functional renal alterations caused by Bothrops alternatus snake venom: expression and activity of Na+/K+-ATPase. Biochimica et biophysica acta 2011; 1810: 895-906. 65. Perez JD, Colucci JA, Sakata MM, et al. Proteomic approaches in understanding a detected relationship between chemotherapy-induced nephrotoxicity and cell respiration in HK-2 cells. Nephron Physiology 2011; 119: p1-10. 66. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787. 67. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic medicine : a journal of the British Diabetic Association 1998; 15: 539-553. 68. Lacy PE. Electron microscopy of the beta cell of the pancreas. The American journal of medicine 1961; 31: 851-859. 69. Del Prato S, Wishner WJ, Gromada J, et al. Beta-cell mass plasticity in type 2 diabetes. Diabetes, obesity & metabolism 2004; 6: 319-331. 70. Steil GM, Trivedi N, Jonas JC, et al. Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. American journal of physiology Endocrinology and metabolism 2001; 280: E788-796. 71. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110. 72. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820. 73. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-2263. 74. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. The Journal of experimental medicine 2003; 198: 1507-1515. 75. Lim M, Park L, Shin G, et al. Induction of apoptosis of Beta cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Annals of the New York Academy of Sciences 2008; 1150: 311-315. 76. Shu T, Zhu Y, Wang H, et al. AGEs decrease insulin synthesis in pancreatic beta-cell by repressing Pdx-1 protein expression at the post-translational level. PloS one 2011; 6: e18782. 77. Ruster C, Bondeva T, Franke S, et al. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2008; 23: 2179-2191. 78. Kaida Y, Fukami K, Matsui T, et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 2013; 62: 3241-3250. 79. Ko SY, Lin IH, Shieh TM, et al. Cell hypertrophy and MEK/ERK phosphorylation are regulated by glyceraldehyde-derived AGEs in cardiomyocyte H9c2 cells. Cell biochemistry and biophysics 2013; 66: 537-544. 80. Huang JS, Chuang LY, Guh JY, et al. Effects of nitric oxide and antioxidants on advanced glycation end products-induced hypertrophic growth in human renal tubular cells. Toxicological sciences : an official journal of the Society of Toxicology 2009; 111: 109-119. 81. Jitrapakdee S, Wutthisathapornchai A, Wallace JC, et al. Regulation of insulin secretion: role of mitochondrial signalling. Diabetologia 2010; 53: 1019-1032. 82. Cheng MY, Hartl FU, Martin J, et al. Mitochondrial heat-shock protein hsp60 is essential for assembly of proteins imported into yeast mitochondria. Nature 1989; 337: 620-625. 83. Cabiscol E, Belli G, Tamarit J, et al. Mitochondrial Hsp60, resistance to oxidative stress, and the labile iron pool are closely connected in Saccharomyces cerevisiae. The Journal of biological chemistry 2002; 277: 44531-44538. 84. Christensen JH, Nielsen MN, Hansen J, et al. Inactivation of the hereditary spastic paraplegia-associated Hspd1 gene encoding the Hsp60 chaperone results in early embryonic lethality in mice. Cell stress & chaperones 2010; 15: 851-863. 85. Magen D, Georgopoulos C, Bross P, et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. American journal of human genetics 2008; 83: 30-42. 86. Hansen JJ, Durr A, Cournu-Rebeix I, et al. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. American journal of human genetics 2002; 70: 1328-1332. 87. Kleinridders A, Lauritzen HP, Ussar S, et al. Leptin regulation of Hsp60 impacts hypothalamic insulin signaling. The Journal of clinical investigation 2013; 123: 4667-4680. 88. Chen YW, Huang CF, Tsai KS, et al. The role of phosphoinositide 3-kinase/Akt signaling in low-dose mercury-induced mouse pancreatic beta-cell dysfunction in vitro and in vivo. Diabetes 2006; 55: 1614-1624. 89. Guan SS, Sheu ML, Wu CT, et al. ATP synthase subunit-beta down-regulation aggravates diabetic nephropathy. Scientific reports 2015; 5: 14561. 90. Bonner-Weir S. beta-cell turnover: its assessment and implications. Diabetes 2001; 50 Suppl 1: S20-24. 91. Crawford LA, Guney MA, Oh YA, et al. Connective tissue growth factor (CTGF) inactivation leads to defects in islet cell lineage allocation and beta-cell proliferation during embryogenesis. Mol Endocrinol 2009; 23: 324-336. 92. Paris M, Bernard-Kargar C, Berthault MF, et al. Specific and combined effects of insulin and glucose on functional pancreatic beta-cell mass in vivo in adult rats. Endocrinology 2003; 144: 2717-2727. 93. Ahren J, Ahren B, Wierup N. Increased beta-cell volume in mice fed a high-fat diet: a dynamic study over 12 months. Islets 2010; 2: 353-356. 94. Wei FY, Suzuki T, Watanabe S, et al. Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice. The Journal of clinical investigation 2011; 121: 3598-3608. 95. Jonas JC, Sharma A, Hasenkamp W, et al. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. The Journal of biological chemistry 1999; 274: 14112-14121. 96. Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes care 1999; 22 Suppl 2: B65-71. 97. Fosmark DS, Torjesen PA, Kilhovd BK, et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental 2006; 55: 232-236. 98. Liu Y, Ma Y, Wang R, et al. Advanced glycation end products accelerate ischemia/reperfusion injury through receptor of advanced end product/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells. Antioxidants & redox signaling 2011; 15: 1769-1778. 99. Susztak K, Ciccone E, McCue P, et al. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS medicine 2005; 2: e45. 100. Shi L, Yu X, Yang H, et al. Advanced glycation end products induce human corneal epithelial cells apoptosis through generation of reactive oxygen species and activation of JNK and p38 MAPK pathways. PloS one 2013; 8: e66781. 101. Li J, Liu D, Sun L, et al. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. Journal of the neurological sciences 2012; 317: 1-5. 102. Byun K, Bayarsaikhan E, Kim D, et al. Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. PloS one 2012; 7: e37917. 103. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Annals of the New York Academy of Sciences 2011; 1243: 88-102. 104. Mizukami H, Wada R, Koyama M, et al. Augmented beta cell loss and mitochondrial abnormalities in sucrose-fed GK rats. Virchows Archiv : an international journal of pathology 2008; 452: 383-392. 105. Zhou LY, Liu JP, Wang K, et al. Mitochondrial function in cardiac hypertrophy. International journal of cardiology 2013; 167: 1118-1125. 106. Anello M, Lupi R, Spampinato D, et al. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 2005; 48: 282-289. 107. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic beta-cells. Nature 2001; 414: 807-812. 108. Ward MS, Fortheringham AK, Cooper ME, et al. Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Current opinion in pharmacology 2013; 13: 654-661. 109. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996; 381: 571-579. 110. Magnoni R, Palmfeldt J, Christensen JH, et al. Late onset motoneuron disorder caused by mitochondrial Hsp60 chaperone deficiency in mice. Neurobiology of disease 2013; 54: 12-23. 111. Bie AS, Palmfeldt J, Hansen J, et al. A cell model to study different degrees of Hsp60 deficiency in HEK293 cells. Cell stress & chaperones 2011; 16: 633-640. 112. Corydon TJ, Hansen J, Bross P, et al. Down-regulation of Hsp60 expression by RNAi impairs folding of medium-chain acyl-CoA dehydrogenase wild-type and disease-associated proteins. Molecular genetics and metabolism 2005; 85: 260-270. 113. Lopez MF, Berggren K, Chernokalskaya E, et al. A comparison of silver stain and SYPRO Ruby Protein Gel Stain with respect to protein detection in two-dimensional gels and identification by peptide mass profiling. Electrophoresis 2000; 21: 3673-3683. 114. Zhang S, Liu J, Chen Y, et al. A novel strategy for MALDI-TOF MS analysis of small molecules. Journal of the American Society for Mass Spectrometry 2010; 21: 154-160. 115. Holcapek M, Jirasko R, Lisa M. Recent developments in liquid chromatography-mass spectrometry and related techniques. Journal of chromatography A 2012; 1259: 3-15. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51282 | - |
dc.description.abstract | 腎臟病變與胰島β細胞功能異常是高血糖狀態下常見的併發症。高血糖會促使糖化終產物 (advanced glycation end products, AGEs) 生成,並堆積在糖尿病患者大部分的組織。 AGEs引發ROS的產生,並活化訊息傳遞路徑去誘導腎臟纖維化與胰島β細胞肥大,但對於AGEs促使併發症生成的分子機制仍不清楚。因此,本篇論文是利用蛋白質體學的技術搜尋出與兩個與AGEs引發併發症相關的蛋白質-ATP合成酶β次單元 (ATP synthase subunit-β, ATP5b) 與熱休克蛋白60 (heat shock protein 60, HSP60),並分成兩個部分進行探討。
第一部分,我們將研究ATP5b在糖尿病腎病變所扮演的角色。與對照組相比,我們觀察到糖尿病的小鼠,其組織型態產生改變、纖維化、α-平滑肌肌动蛋白 ( α-smooth muscle actin, α-SMA)、AGEs和ATP5b有明顯的增加。ATP5b主要表現在腎小管的位置,但腎絲球的部位不明顯。AGEs透過腎小管細胞表面對應的接受器 (the receptor for AGEs, RAGE),促使ATP5b及纖維化蛋白的明顯的表現,並降低細胞ATP的含量。而在糖尿病小鼠的腎臟組織及AGEs處理的後的腎小管細胞皆有觀察到氧化壓力明顯增加。然而,抗氧化藥物N-acetylcysteine可以抑制AGEs誘導ATP5b以及結締組織生長因子 (connective tissue growth factor, CTGF) 蛋白質表現增加的現象。此外,當腎小管細胞的ATP5b表現被抑制後,在AGEs的作用下,會使α-SMA and CTGF表現更加顯著,且 CTGF promoter 活性也增加。最後將糖尿病小鼠的腎臟ATP5b表現抑制後可發現,血清肌酸酐以及腎臟纖維化的現象更加明顯。上述結果顯示,在糖尿病的狀態下,大量表現ATP5b對於 AGEs造成的腎臟病變具有保護的角色。 第二部分,我們要探討HSP60在糖尿病引起的胰島β細胞肥大及功能缺陷所扮演的角色。HSP60是一種粒線體的伴護子,而AGEs已經被認為會對β細胞功能造成影響。我們假設第二型糖尿病引起的β細胞肥大現象是透過HSP60之異常調控路徑,使得AGEs誘導細胞肥大及功能缺失。我們利用糖尿病小鼠以及β細胞去研究 AGEs誘導細胞肥大與功能異常中HSP60所扮演的角色。與對照組相比,糖尿病患者的胰臟切片顯示,胰島部位有肥大、AGEs含量增加以及HSP60表現下降的現象。而在12週大的糖尿病小鼠也發現細胞肥大標記p27Kip1增加、AGEs和RAGE表現增加,而HSP60、胰島素與ATP含量皆下降。當β細胞給予RAGE抗體中和反應後,低濃度AGEs所造成的細胞肥大、p27Kip1表現增加、HSP60表現下降、胰島素分泌與ATP含量降低的現象皆被抑制。大量的HSP60表現可呈現細胞保護的效果,進而去抵抗AGEs所誘導的β細胞肥大、功能異常以及ATP含量下降。另外,AGEs降低β細胞的HSP60表現也與氧化壓力有關。綜合上述,這些發現顯示,當在糖尿病的態下,HSP60可能是一個做為AGE-RAGE訊息傳遞誘導β細胞肥大與功能異常的標的物。 | zh_TW |
dc.description.abstract | Diabetic nephropathy and pancreatic β-cell dysfunction are the major complications caused by hyperglycemic condition. Hyperglycemia increases formation of advanced glycation end products (AGEs) and accumulates to most of tissue in diabetes patients. AGEs induce ROS generation and activation of signal transduction to cause renal fibrosis and islet β cell hypertrophy, but the mechanisms are still unclear. Here we investigated the relation of factors and mechanism which was involved in AGEs caused renal fibrosis and β-cell hypertrophy and dysfunction in type 2 diabetes (T2D) mice. Moreover, we utilized proteomics technique to find out two proteins –ATP synthase subunit-β (ATP5b) and heat shock protein 60 (HSP60) which were involved AGEs-induced diabetic nephropathy and pancreatic β-cell dysfunction, respectively. Here, we divided two parts of this study for discussion.
In the first part of this study, we investigated the role of ATP5b in diabetic nephropathy. Histopathological changes, fibrosis, and protein expressions of α-smooth muscle actin (α-SMA), AGEs, and ATP5b were obviously observed in the kidneys of db/db diabetic mice as compared with the control db/m+ mice. The increased ATP5b expression was majorly observed in diabetic renal tubules and was notably observed to locate in cytoplasm of tubule cells, but no significant increase of ATP5b in diabetic glomeruli. AGEs significantly increased protein expression of ATP5b and fibrotic factors and decreased ATP content in cultured renal tubular cells via a AGEs-receptor for AGEs (RAGE) axis pathway. Oxidative stress was also induced in diabetic kidneys and AGEs-treated renal tubular cells. The increase of ATP5b and connective tissue growth factor (CTGF) protein expression in AGEs-treated renal tubular cells was reversed by antioxidant N-acetylcysteine. Moreover, ATP5b-siRNA transfection augmented the increased protein expression of α-SMA and CTGF and CTGF promoter activity in AGEs-treated renal tubular cells. Finally, the in vivo ATP5b-siRNA delivery significantly enhanced renal fibrosis and serum creatinine in db/db mice with ATP5b down-regulation. These findings suggest that increased ATP5b plays an important adaptive or protective role in decreasing the rate of AGEs induced renal fibrosis during diabetic condition. In the second part of this study, we investigated the role of HSP60 in pancreatic islet hypertrophy and dysfunction during hyperglycemia condition. HSP60 is a mitochondrial chaperone. AGEs have been shown to modulate the β-cell function. We hypothesized that AGEs induced β-cell hypertrophy and dysfunction through a HSP60 dysregulation pathway during the stage of islet/β-cell hypertrophy of T2D. We investigated the role of HSP60 in AGEs-induced β-cell hypertrophy and dysfunction using the models of diabetic mice and cultured β-cells. Pancreatic sections from diabetic patient showed islet hypertrophy, increased AGEs level, and decreased HSP60 level as compared with normal subject. Hypertrophy, increased levels of Cyclin-dependent kinase inhibitor 1B (p27Kip1), AGEs, and RAGE, and decreased levels of HSP60, insulin, and ATP content were obviously observed in pancreatic islets of 12-week-old db/db diabetic mice. Low-concentration AGEs significantly induced the cell hypertrophy, increased the p27Kip1 expression, and decreased the HSP60 expression, insulin secretion, and ATP content in cultured β-cells, which could be reversed by RAGE neutralizing antibody. HSP60 overexpression showed cytoprotective effects against AGEs-induced hypertrophy, dysfunction, and ATP reduction in β-cells. Moreover, oxidative stress was involved in the AGEs-decreased HSP60 expression in β-cells. Taken together, these findings highlight a novel mechanism by which HSP60 is a possible target for AGEs-RAGE axis-induced β-cell hypertrophy and dysfunction under diabetic hyperglycemia. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:29:22Z (GMT). No. of bitstreams: 1 ntu-105-D99447002-1.pdf: 12702037 bytes, checksum: 43856f4c87900cad1be6693154c1c863 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員審定書 1
誌謝 2 中文摘要 3 Abstract 5 Abbreviation 8 List of Tables 9 List of Figures 10 Chapter 1: ATP synthase subunit-β down-regulation aggravates diabetic nephropathy 12 1.1 Introduction 13 1.2 Materials and Methods 16 1.3 Results 29 1.4 Discussion 35 1.5 Conclusions 39 Chapter 2: The pathological role of advanced glycation end products-downregulated heat shock protein 60 in islet β-cell hypertrophy and dysfunction 40 2.1 Introduction 41 2.2 Materials and Methods 44 2.3 Results 51 2.4 Discussion 55 2.5 Conclusions 60 References 61 Tables 75 Figures and figure legends 78 Appendix 109 | |
dc.language.iso | en | |
dc.title | 以蛋白質體學探討糖尿病相關腎臟病變及胰臟胰島異常之分子機制 | zh_TW |
dc.title | Studies on Molecular Mechanisms of Diabetes-related Nephropathy and Pancreatic Islet Abnormality Using Technology of Proteomics | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 姜至剛,蕭水銀,林琬琬,楊榮森 | |
dc.subject.keyword | 糖化終產物,糖尿病腎病變,腎纖維化,ATP5b,β細胞,細胞肥大,熱休克蛋白60, | zh_TW |
dc.subject.keyword | advanced glycation end products,diabetic nephropathy,ATP5b,renal fibrosis,β-cell hypertrophy,heat shock protein 60, | en |
dc.relation.page | 109 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-02-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 12.4 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。